SEARCH

SEARCH BY CITATION

References

  • 1
    Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981; 80:800809.MEDLINE
  • 2
    Burroughs AK, Mezzanotte G, Phillips A, McCormick PA, McIntyre N. Cirrhotics with variceal hemorrhage: The importance of the time interval between admission and the start of analysis for survival and rebleeding rates. Hepatology 1989; 9:801807.MEDLINE
  • 3
    De Dombal FT, Clarke JR, Clamp SE, Malizia G, Kotwal MR, Morgan AG. Prognostic factors in upper G.I. bleeding. Endoscopy 1986; 18(Suppl 2):610.MEDLINE
  • 4
    D'Amico G, Morabito A, Pagliaro L. Six-week prognostic indicators in upper gastro-intestinal haemorrhage in cirrhosis. In: DianzaniMU, GentiliniP, eds. Frontiers in Gastrointestinal Research: Chronic Liver Disease. Basel: Karger, 1986;247257.
  • 5
    Smith JL, Graham DY. Variceal Hemorrhage. A critical evaluation of survival analysis. Gastroenterology 1982; 82:96873.MEDLINE
  • 6
    Sorensen TIA. Definition of death in relation to variceal bleeding. In: BurroughsAK, eds. Methodology and reviews of clinical trials in portal hypertension. Amsterdam: Elsevier Science Publisher BV (Biomedical Division), 1987;3139.
  • 7
    De Franchis R, Pascal JP, Ancona E, Burroughs AK, Henderson M, Fleig W, Groszmann R, et al. Definitions, methodology and therapeutic strategies in portal hypertension. A consensus development workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990. J Hepatol 1992; 15:256261.MEDLINE
  • 8
    Pagliaro L, de Franchis R. Where were we? A summary of the issues where consensus was reached at Baveno I. In: deFranchis R, eds. Portal Hypertension II. Proceedings of the second Baveno international consensus workshop on definitions, methodology and therapeutic strategies. Oxford: Blackwell Science, 1996;19.
  • 9
    D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22:332342.MEDLINE
  • 10
    Infante-Rivard C, Esnaola S, Villeneuve JP. Role of endoscopic variceal sclerotherapy in the long term management of variceal bleeding: a meta-analysis. Gastroenterology 1989;10871092.
  • 11
    Burroughs AK, McCormick PA, Hughes MD, Sprengers D, D'Heygere F, McIntyre N. Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding. Emergency control and prevention of early variceal rebleeding. Gastroenterology 1990; 99:13881395.MEDLINE
  • 12
    Sung JJY, Chung SCS, Yung MY, Lai CW, Lau JYW, Lee YT, Leung VKS, et al. Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet 1995; 346:16661669.MEDLINE
  • 13
    Besson I, Ingrand P, Person B, Boutroux D, Heresbach D, Bernard P, Hochain P, et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 1995; 333:555560.MEDLINE
  • 14
    Fiaccadori F, Pedretti G, Biraghi M, Arcidiacono R. Terlypressin and endoscopic sclerotherapy control variceal bleeding and prevent early rebleeding in cirrhotic patients. Curr Ther Res 1993; 54:110.
  • 15
    Marbet UA, Straumann A, Gyr KE, Beglinger C, Shaub N, Vogtlin J, Loosli J, et al. Reduction in early recurrence of variceal bleeding by propranolol. Scand J Gastroenterol 1988; 23:369374.MEDLINE
  • 16
    Villeneuve JP, Pomier-Layrargues G, Infante-Rivard C, Willems B, Huet PM, Marleau D, Viallet A. Propranolol for the prevention of recurrent variceal hemorrhage: a controlled trial. Hepatology 1986; 6:12391243.MEDLINE
  • 17
    Garden OJ, Mills PR, Birnie GG, Murray GD, Carter DC. Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic patients. Gastroenterology 1990; 98:185190.MEDLINE
  • 18
    Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis. Ann Intern Med 1995; 123:280287.MEDLINE
  • 19
    Navasa M, Bosch J, Chesta J. Haemodynamic effects of subcutaneous administration of S M S 201–995 a long acting somatostatin analogue in patients with cirrhosis and portal hypertension [abstract]. J Hepatol 1988; 7(Suppl 1):S64.
  • 20
    Eriksson LS, Brundin T, Soderlund C, Wahren J. Haemodynamic effects of a long-acting somatostatin analogue in patients with liver cirrhosis. Scand J Gastroenterol 1987; 22:919925.MEDLINE
  • 21
    McCormick PA, Dick R, Siringo S. Octreotide reduces azygous blood flow in cirrhotic patients with portal hypertension. Eur J Gastroenterol Hepatol 1990; 2:489492.
  • 22
    Sung JJY, Chung SCS, Lai CW, Chan FKL, Leung JWC, Yung MY, Kassiandes C, et al. Octreotide infusion or emergency sclerotherapy for variceal haemorrhage. Lancet 1993; 342:637641.MEDLINE
  • 23
    Lamberts SWJ, van der Lely AJ, de Herder WW, Hofland L. Octreotide. N Engl J Med 1996;246254.
  • 24
    Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutic trials. J Chronic Dis 1967; 20:637648.MEDLINE
  • 25
    Diamond GA, Denton TA. Alternative perspective on the biased foundations of medical technology assessment. Ann Intern Med 1993; 118:455464.MEDLINE
  • 26
    Burroughs AK (Chairman), Alexandrino P, Calès P, Fleig W, Grace N, Minoli G, Siringo S. ‘Sore Points’. A review of the points where there was disagreement at Baveno I, and an attempt to reach consensus. In: deFranchis R, eds. Portal Hypertension II. Proceedings of the Second Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies. Oxford: Blackwell Science. 1996;1017.
  • 27
    Pugh RNH, Murray-Lyon M, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646649.MEDLINE
  • 28
    Italian Multicenter Project for Propranolol in Prevention of Bleeding. Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients. J Hepatol 1989; 9:7583.MEDLINE
  • 29
    Poynard T, Lebrec D, Hillon P, Sayegh R, Bernau J, Naveau S, Chaput JC, et al. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a prospective study of factors associated with rebleeding. Hepatology 1987; 3:447451.
  • 30
    McKee RF, Garden OJ, Anderson JR, Carter DC. A trial of elective versus on demand sclerotherapy in “poor risk” patients with variceal hemorrhage. Endoscopy 1994; 26:474477.MEDLINE
  • 31
    D'Amico G, Traina M, Vizzini G, Tinè F, Politi F, Montalbano L, Luca A, et al. Terlipressin or vasopressin plus transdermal nitroglycerin in a treatment strategy for digestive bleeding in cirrhosis. A randomized clinical trial. J Hepatol 1994; 20:206212.MEDLINE
  • 32
    Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: Wiley, 1989.
  • 33
    Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV. Design and analysis of randomized clinical trials requiring prolonged observation. II. Analysis and examples. Br J Cancer 1977; 35:139.MEDLINE
  • 34
    Cox DR. The Analysis of Binary Data. London: Methuen, 1970.
  • 35
    Harrell FE, Lee KL, Matchar DB, Reichert TA. Regression models for prognostic prediction: advantages, problems and suggested solutions. Cancer Treat Rep 1985; 69:10711077.MEDLINE
  • 36
    Primignani M, Andreoni B, Carpinelli L, Capria A, Rocchi G, Lorenzini I, Lorenzini I, et al. Sclerotherapy plus octreotide versus sclerotherapy alone in the prevention of early rebleeding from esophageal varices: A randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 1995; 21:13221327.MEDLINE
  • 37
    Jenkins SA, Baxter JN, Critchley M, Kingsnorth AN, Makin Carol A, Ellenbogen S, Grime SJ, et al. Randomised trial of octreotide for long term management of cirrhosis after variceal haemorrhage. BMJ 1997; 315:13381341.MEDLINE